| abstract |
The present invention relates to prodrugs 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro- 1H-1,2,4-triazol-1-yl}methyl)-1-[3-(trifluoromethyl)-pyridin-2-yl]-1H-1,2,4-triazol-5-carboxamide, 3-( {3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazole- 1-yl}methyl)-1-[2-(trifluoromethyl)-phenyl]-1H-1,2,4-triazol-5-carboxamide and 3-({3-(4-chlorophenyl)-5-ox o- 4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-t riazol-1-yl}methyl)-1-(3-chloropyridine -2-yl)-1H-1,2,4-triazol-5-car boxamide, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of renal and cardiovascular diseases. |